OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Part of paid clinical trials in Baton Rouge, Louisiana.

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00193154
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • OSI-774 — DRUG
    150mg PO, days 1-28, cycle repeated every 28 days
  • Bevacizumab — DRUG
    10mg/kg, IV infusion, Days 1 and 15, 28 day cycles

Study Details

In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology (VHL/HIF/VEGF/EGFr).

Key Dates

First listed
Sep 19, 2005
Start date
Feb 28, 2003
Status verified
Mar 2014
Primary completion
Jan 31, 2004
Completion
Mar 31, 2014

Study Design

Enrollment
63 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: OSI-774 & bevacizumab
    OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.

Primary Outcome Measure

Efficacy of the combination of Tarceva and Avastin [ Time Frame: 18 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
Medical Oncology LLCBaton RougeLouisiana70809-
Grand Rapids Oncology ProgramGrand RapidsMichigan49503-

Find similar trials in Baton Rouge, LA

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Medical Oncology LLC· Baton Rouge, LAGrand Rapids Oncology Program· Grand Rapids, MI

Related Studies